Mayer Rokitansky Kuster Hauser SyndromePhase 4NCT07865559
Vaginal Lactobacillus for Postoperative Microecology and Mucosal Repair in MRKH Syndrome
A Phase 4 study testing postoperative application of vaginal Lactobacillus capsule and routine care in people with Mayer Rokitansky Kuster Hauser Syndrome, run by Obstetrics & Gynecology Hospital of Fudan University.
Trial summary
This study is aimed to evaluate the promoting effects of vaginal Lactobacillus capsule on microecological reconstruction and mucosal repair of the neovagina after biological graft vaginoplasty in patients with MRKH syndrome, , through a randomized controlled trial (RCT). Read more about this study
- Who is it for?
- Ages 18 to 35 years, women only
- Conditions the study is for
- Mayer Rokitansky Kuster Hauser Syndrome
- What is being tested?
- postoperative application of vaginal Lactobacillus capsule and routine care
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- No sites listed yet
- Study dates
- 1 Nov 2026to 30 Jun 2028
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Patients diagnosed with MRKH syndrome;
- Undergoing initial surgical treatment;
- Undergoing biological graft vaginoplasty;
- Age: 18-35 years;
- Voluntarily participating in this study, signing the informed consent form, with good compliance and cooperation with follow-up.
Who cannot join
- History of previous vaginoplasty or other related treatments;
- History of diabetes mellitus or systemic immune system diseases;
- Concurrent severe medical or surgical diseases that make the patient unable to tolerate drug therapy;
- Inability or unwillingness to sign the informed consent form;
- Inability or unwillingness to comply with the study requiremen.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Xiaoyan Tang, Doctor contact
About this study
Official title: Effects of Vaginal Lactobacillus Capsule on Postoperative Vaginal Microecology and Mucosal Repair in Patients With Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome
This study is aimed to evaluate the promoting effects of vaginal Lactobacillus capsule on microecological reconstruction and mucosal repair of the neovagina after biological graft vaginoplasty in patients with MRKH syndrome, , through a randomized controlled trial (RCT).
Read the detailed description
This study is planned to use a randomized controlled trial design and enroll 32 patients with MRKH syndrome who have undergone biological graft vaginoplasty. The patients will be randomly assigned 1:1 to an intervention group (postoperative application of vaginal Lactobacillus capsule) and a control group (routine care). In both groups, vaginal secretions will be collected before treatment and at 1, 3, 6, and 12 months postoperatively; gynecological examinations will be performed; symptom and sign record forms will be completed; and adverse reactions will be documented. The following outcome measures will be evaluated: (1) Primary efficacy outcome measures: microecology-related indicators, including routine vaginal secretion testing, Lactobacillus counts, and microbial diversity analysis. (2) Secondary efficacy outcome measures: neovaginal length and width, the degree of mucosal squamous epithelial metaplasia, the incidence of adverse events, and sexual function scale scores.
- Conditions
- Mayer Rokitansky Kuster Hauser Syndrome
- Being tested
- postoperative application of vaginal Lactobacillus capsule, routine care
- Keywords
- MRKH syndrome, Neovaginoplasty, vaginal Lactobacillus, Microecology, Vaginal repair
- Medical subject headings
- Mullerian aplasia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
postoperative application of vaginal Lactobacillus capsuleBiological
The patients in intervention group (n=16) will wash the vulva with clean water every night and then insert one Dingjunsheng capsule (0.25 g/capsule, containing Lactobacillus delbrueckii ≥0.25 × 10⁶ CFU/mL; for vaginal use; Lot No.: 20120804; Inner Mongolia Shuangqi Pharmaceutical Co., Ltd.) deep into the vagina once nightly for 10 consecutive days. The methods of disinfecting and wearing the vaginal mold will be the same in both groups.
routine careOther
The patients in control group (n=16) will wash the vulva with clean water every night without using any medication and wear the vaginal mold. The methods of disinfecting and wearing the vaginal mold will be the same in both groups.
| Study group | Role | What they receive |
|---|---|---|
| Arm1: intervention group | Experimental | postoperative application of vaginal Lactobacillus capsule Receives: Biological: postoperative application of vaginal Lactobacillus capsule |
| Arm 2: control group | Other | routine care without application of vaginal Lactobacillus capsule Receives: Other: routine care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lactobacillus count
Vaginal secretions were collected for Lactobacillus counting. Lactobacilli were counted according to the Nugent criteria. The number of lactobacilli per high-power field (HPF): <1 = (+), 1-4 = (++), 5-30 = (+++), and >30 = (++++). Among these, (+++) and (++++) represent the normal lactobacillus count in healthy individuals. (+++) and (++++) are considered effective/valid; (+) and (++) are ineffective/invalid.
Measured: 1 month postoperatively
Lactobacillus count
Vaginal secretions were collected for Lactobacillus counting. Lactobacilli were counted according to the Nugent criteria. The number of lactobacilli per high-power field (HPF): <1 = (+), 1-4 = (++), 5-30 = (+++), and >30 = (++++). Among these, (+++) and (++++) represent the normal lactobacillus count in healthy individuals. (+++) and (++++) are considered effective/valid; (+) and (++) are ineffective/invalid.
Measured: 3 months postoperatively
Lactobacillus count
Vaginal secretions were collected for Lactobacillus counting. Lactobacilli were counted according to the Nugent criteria. The number of lactobacilli per high-power field (HPF): <1 = (+), 1-4 = (++), 5-30 = (+++), and >30 = (++++). Among these, (+++) and (++++) represent the normal lactobacillus count in healthy individuals. (+++) and (++++) are considered effective/valid; (+) and (++) are ineffective/invalid.
Measured: 6 months postoperatively
Lactobacillus count
Vaginal secretions were collected for Lactobacillus counting: Lactobacilli were counted according to the Nugent criteria. The number of lactobacilli per high-power field (HPF): <1 = (+), 1-4 = (++), 5-30 = (+++), and >30 = (++++). Among these, (+++) and (++++) represent the normal Lactobacillus count in healthy individuals. (+++) and (++++) are considered effective; (+) and (++) are ineffective.
Measured: 12 months postoperatively
Secondary outcomes (8)
length of neovagina
Length of neovagina was measured using a sterile disposable paper ruler, and the results were expressed in centimeter (cm).
Measured: 1 month postoperatively
length of neovagina
Length of neovagina was measured using a sterile disposable paper ruler, and the results were expressed in centimeter (cm).
Measured: 3 months postoperatively
length of neovagina
Length of neovagina was measured using a sterile disposable paper ruler, and the results were expressed in centimeter (cm).
Measured: 6 months postoperatively
length of neovagina
Length of neovagina was measured using a sterile disposable paper ruler, and the results were expressed in centimeter (cm).
Measured: 12 months postoperatively
percentage of squamous epithelialization of neovagina
During gynecological examination, after the neovagina was opened with a vaginal speculum, the total neovaginal length and the length of the squamous metaplastic portion were measured separately using a disposable sterile paper ruler. Percentage of squamous epithelialization of neovagina was calculated as the length of the squamous metaplastic portion divided by the total neovaginal length. A higher percentage of squamous epithelialization indicates a better outcome of vaginoplasty.
Measured: 1 month postoperatively
percentage of squamous epithelialization of neovagina
During gynecological examination, after the neovagina was opened with a vaginal speculum, the total neovaginal length and the length of the squamous metaplastic portion were measured separately using a disposable sterile paper ruler. Percentage of squamous epithelialization of neovagina was calculated as the length of the squamous metaplastic portion divided by the total neovaginal length. A higher percentage of squamous epithelialization indicates a better outcome of vaginoplasty.
Measured: 3 months postoperatively
percentage of squamous epithelialization of neovagina
During gynecological examination, after the neovagina was opened with a vaginal speculum, the total neovaginal length and the length of the squamous metaplastic portion were measured separately using a disposable sterile paper ruler. Percentage of squamous epithelialization of neovagina was calculated as the length of the squamous metaplastic portion divided by the total neovaginal length. A higher percentage of squamous epithelialization indicates a better outcome of vaginoplasty.
Measured: 6 months postoperatively
Sexual life quality
Sexual life quality was assessed by Female Sexual Function Index (FSFI). The FSFI is a standardized self-report scale used to evaluate female sexual function over the past 4 weeks. It was developed by Rosen et al. in 2000 and consists of 19 items across 6 domains, covering sexual desire, sexual arousal, vaginal lubrication, orgasm, sexual satisfaction, and dyspareunia. Each domain has a maximum score of 6 points (after adjustment), and the total score ranges from 2.0 to 36. Lower scores indicate more obvious sexual function problems.
Measured: 12 months postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2026
- Study start1 Nov 2026 (estimated)
- Primary completion30 May 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Mayer Rokitansky Kuster Hauser SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 32 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Obstetrics & Gynecology Hospital of Fudan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Keqin Hua, Obstetrics & Gynecology Hospital of Fudan University
- Investigators
- Keqin Hua, Doctor, Principal investigator, Obstetrics & Gynecology Hospital of Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07865559
- Sponsor's protocol ID
- 2026-57
- Status last verified
- Sep 2026
- First submitted
- 27 Sep 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Debray R, Herbert RA, Jaffe AL, Crits-Christoph A, Power ME, Koskella B. Priority effects in microbiome assembly. Nat Rev Microbiol. 2022 Feb;20(2):109-121. doi: 10.1038/s41579-021-00604-w. Epub 2021 Aug 27.
PubMed 34453137Chen N, Hao L, Zhang Z, Qin C, Jie Z, Pan H, Duan J, Huang X, Zhang Y, Gao H, Lu R, Sun T, Yang H, Shi J, Liang M, Guo J, Gao Q, Zhao X, Dou Z, Xiao L, Zhang S, Jin X, Xu X, Yang H, Wang J, Jia H, Zhang T, Kristiansen K, Chen C, Zhu L. Insights into the assembly of the neovaginal microbiota in Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome patients. Nat Commun. 2024 Sep 6;15(1):7808. doi: 10.1038/s41467-024-52102-1.
PubMed 39242555Huang X, Lin R, Mao B, Tang X, Zhao J, Zhang Q, Cui S. Lactobacillus crispatus CCFM1339 Inhibits Vaginal Epithelial Barrier Injury Induced by Gardnerella vaginalis in Mice. Biomolecules. 2024 Feb 18;14(2):240. doi: 10.3390/biom14020240.
PubMed 38397477Sharma M, Chopra C, Mehta M, Sharma V, Mallubhotla S, Sistla S, Sistla JC, Bhushan I. An Insight into Vaginal Microbiome Techniques. Life (Basel). 2021 Nov 13;11(11):1229. doi: 10.3390/life11111229.
PubMed 34833105Committee on Adolescent Health Care. ACOG Committee Opinion No. 728: Mullerian Agenesis: Diagnosis, Management, And Treatment. Obstet Gynecol. 2018 Jan;131(1):e35-e42. doi: 10.1097/AOG.0000000000002458.
PubMed 29266078Wagner A, Brucker SY, Ueding E, Grober-Gratz D, Simoes E, Rall K, Kronenthaler A, Schaffeler N, Rieger MA. Treatment management during the adolescent transition period of girls and young women with Mayer-Rokitansky-Kuster-Hauser syndrome (MRKHS): a systematic literature review. Orphanet J Rare Dis. 2016 Nov 16;11(1):152. doi: 10.1186/s13023-016-0536-6.
PubMed 27852280
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Vaginal Lactobacillus Capsule on Postoperative Vaginal Microecology and Mucosal Repair in Patients With Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome
- ClinicalTrials.gov ID
- NCT07865559
- Acronym / sponsor ID
- 2026-57
- Conditions
- Mayer Rokitansky Kuster Hauser Syndrome
- Keywords
- MRKH syndrome, Neovaginoplasty, vaginal Lactobacillus, Microecology, Vaginal repair
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 32 participants (estimated)
- Lead sponsor
- Obstetrics & Gynecology Hospital of Fudan UniversityUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 30 May 2028 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 8 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is aimed to evaluate the promoting effects of vaginal Lactobacillus capsule on microecological reconstruction and mucosal repair of the neovagina after biological graft vaginoplasty in patients with MRKH syndrome, , through a randomized controlled trial (RCT).
Detailed description
This study is planned to use a randomized controlled trial design and enroll 32 patients with MRKH syndrome who have undergone biological graft vaginoplasty. The patients will be randomly assigned 1:1 to an intervention group (postoperative application of vaginal Lactobacillus capsule) and a control group (routine care). In both groups, vaginal secretions will be collected before treatment and at 1, 3, 6, and 12 months postoperatively; gynecological examinations will be performed; symptom and sign record forms will be completed; and adverse reactions will be documented. The following outcome measures will be evaluated: (1) Primary efficacy outcome measures: microecology-related indicators, including routine vaginal secretion testing, Lactobacillus counts, and microbial diversity analysis. (2) Secondary efficacy outcome measures: neovaginal length and width, the degree of mucosal squamous epithelial metaplasia, the incidence of adverse events, and sexual function scale scores.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm1: intervention group | Experimental | Biological: postoperative application of vaginal Lactobacillus capsulepostoperative application of vaginal Lactobacillus capsule |
| Arm 2: control group | Other | Other: routine careroutine care without application of vaginal Lactobacillus capsule |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Patients diagnosed with MRKH syndrome;
- Undergoing initial surgical treatment;
- Undergoing biological graft vaginoplasty;
- Age: 18-35 years;
- Voluntarily participating in this study, signing the informed consent form, with good compliance and cooperation with follow-up.
Key exclusion criteria (5 listed)
- History of previous vaginoplasty or other related treatments;
- History of diabetes mellitus or systemic immune system diseases;
- Concurrent severe medical or surgical diseases that make the patient unable to tolerate drug therapy;
- Inability or unwillingness to sign the informed consent form;
- Inability or unwillingness to comply with the study requiremen.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| postoperative application of vaginal Lactobacillus capsuleThe patients in intervention group (n=16) will wash the vulva with clean water every night and then insert one Dingjunsheng capsule (0.25 g/capsule, containing Lactobacillus delbrueckii ≥0.25 × 10⁶ CFU/mL; for vaginal use; Lot No.: 20120804; Inner Mongolia Shuangqi Pharmaceutical Co., Ltd.) deep into the vagina once nightly for 10 consecutive days. The methods of disinfecting and wearing the vaginal mold will be the same in both groups. | Biological | Arm1: intervention group |
| routine careThe patients in control group (n=16) will wash the vulva with clean water every night without using any medication and wear the vaginal mold. The methods of disinfecting and wearing the vaginal mold will be the same in both groups. | Other | Arm 2: control group |
Primary outcome
Lactobacillus count
Time frame: 1 month postoperatively
Vaginal secretions were collected for Lactobacillus counting. Lactobacilli were counted according to the Nugent criteria. The number of lactobacilli per high-power field (HPF): <1 = (+), 1-4 = (++), 5-30 = (+++), and >30 = (++++). Among these, (+++) and (++++) represent the normal lactobacillus count in healthy individuals. (+++) and (++++) are considered effective/valid; (+) and (++) are ineffective/invalid.
Lactobacillus count
Time frame: 3 months postoperatively
Vaginal secretions were collected for Lactobacillus counting. Lactobacilli were counted according to the Nugent criteria. The number of lactobacilli per high-power field (HPF): <1 = (+), 1-4 = (++), 5-30 = (+++), and >30 = (++++). Among these, (+++) and (++++) represent the normal lactobacillus count in healthy individuals. (+++) and (++++) are considered effective/valid; (+) and (++) are ineffective/invalid.
Lactobacillus count
Time frame: 6 months postoperatively
Vaginal secretions were collected for Lactobacillus counting. Lactobacilli were counted according to the Nugent criteria. The number of lactobacilli per high-power field (HPF): <1 = (+), 1-4 = (++), 5-30 = (+++), and >30 = (++++). Among these, (+++) and (++++) represent the normal lactobacillus count in healthy individuals. (+++) and (++++) are considered effective/valid; (+) and (++) are ineffective/invalid.
Lactobacillus count
Time frame: 12 months postoperatively
Vaginal secretions were collected for Lactobacillus counting: Lactobacilli were counted according to the Nugent criteria. The number of lactobacilli per high-power field (HPF): <1 = (+), 1-4 = (++), 5-30 = (+++), and >30 = (++++). Among these, (+++) and (++++) represent the normal Lactobacillus count in healthy individuals. (+++) and (++++) are considered effective; (+) and (++) are ineffective.
8 secondary outcomes
length of neovagina
Time frame: 1 month postoperatively
length of neovagina
Time frame: 3 months postoperatively
length of neovagina
Time frame: 6 months postoperatively
length of neovagina
Time frame: 12 months postoperatively
percentage of squamous epithelialization of neovagina
Time frame: 1 month postoperatively
percentage of squamous epithelialization of neovagina
Time frame: 3 months postoperatively
percentage of squamous epithelialization of neovagina
Time frame: 6 months postoperatively
Sexual life quality
Time frame: 12 months postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Results publication: PubMed 34453137Debray R, Herbert RA, Jaffe AL, Crits-Christoph A, Power ME, Koskella B. Priority effects in microbiome assembly. Nat Rev Microbiol. 2022 Feb;20(2):109-121. doi: 10.1038/s41579-021-00604-w. Epub 2021 Aug 27.
- Results publication: PubMed 39242555Chen N, Hao L, Zhang Z, Qin C, Jie Z, Pan H, Duan J, Huang X, Zhang Y, Gao H, Lu R, Sun T, Yang H, Shi J, Liang M, Guo J, Gao Q, Zhao X, Dou Z, Xiao L, Zhang S, Jin X, Xu X, Yang H, Wang J, Jia H, Zhang T, Kristiansen K, Chen C, Zhu L. Insights into the assembly of the neovaginal microbiota in Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome patients. Nat Commun. 2024 Sep 6;15(1):7808. doi: 10.1038/s41467-024-52102-1.
- Results publication: PubMed 38397477Huang X, Lin R, Mao B, Tang X, Zhao J, Zhang Q, Cui S. Lactobacillus crispatus CCFM1339 Inhibits Vaginal Epithelial Barrier Injury Induced by Gardnerella vaginalis in Mice. Biomolecules. 2024 Feb 18;14(2):240. doi: 10.3390/biom14020240.
- Results publication: PubMed 34833105Sharma M, Chopra C, Mehta M, Sharma V, Mallubhotla S, Sistla S, Sistla JC, Bhushan I. An Insight into Vaginal Microbiome Techniques. Life (Basel). 2021 Nov 13;11(11):1229. doi: 10.3390/life11111229.
- Results publication: PubMed 29266078Committee on Adolescent Health Care. ACOG Committee Opinion No. 728: Mullerian Agenesis: Diagnosis, Management, And Treatment. Obstet Gynecol. 2018 Jan;131(1):e35-e42. doi: 10.1097/AOG.0000000000002458.
- Results publication: PubMed 27852280Wagner A, Brucker SY, Ueding E, Grober-Gratz D, Simoes E, Rall K, Kronenthaler A, Schaffeler N, Rieger MA. Treatment management during the adolescent transition period of girls and young women with Mayer-Rokitansky-Kuster-Hauser syndrome (MRKHS): a systematic literature review. Orphanet J Rare Dis. 2016 Nov 16;11(1):152. doi: 10.1186/s13023-016-0536-6.
- Individual participant dataSharing planned: No
Related trials for Mayer Rokitansky Kuster Hauser Syndrome
Active, not recruiting
The University of Pennsylvania Uterus Transplant for Uterine Factor Infertility Trial
Mayer Rokitansky Kuster Hauser Syndrome, Uterine Agenesis
Recruiting
Uterine Transplant for Women With Absolute Uterine Factor Infertility (AUFI)
Mayer Rokitansky Kuster Hauser Syndrome, Absence of Uterus
Not yet recruitingObservational study
Clinical and Imaging Features in MRKH Syndrome
Mayer Rokitansky Kuster Hauser Syndrome, Müllerian Agenesis
Recruiting
Feasibility Study of Uterine Transplantation From Living Donors in Terms of Efficacy and Safety in Patients With Mayer-Rokitansky-Küster-Hauser Syndrome (MRKH)
Mayer Rokitansky Kuster Hauser Syndrome
Recruiting
Uterus Transplantation From a Multi-organ Donor
Infertility, Female, Mayer Rokitansky Kuster Hauser Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xiaoyan Tang, Doctor contact
Keqin Hua, Doctor principal investigator
Obstetrics & Gynecology Hospital of Fudan University
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing postoperative application of vaginal Lactobacillus capsule and routine care in people with Mayer Rokitansky Kuster Hauser Syndrome, run by Obstetrics & Gynecology Hospital of Fudan University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Keqin Hua, Doctor (+86-021-33189900, huakeqinjiaoshou@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lactobacillus count (time frame: 1 month postoperatively). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07865559, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.